Skip to main content
. 2019 Apr 25;36(3):274–282. doi: 10.1111/pde.13827

Table 1.

Summary of acute hemorrhagic edema of infancy, Henoch‐Schönlein purpura, Kawasaki disease, and Sweet syndrome

Acute hemorrhagic edema of infancy Henoch‐Schönlein purpura Kawasaki disease Sweet syndrome
Typical age of onset 6 mo to 2 y 2‐6 y 13‐24 mo 30‐50 y
Appearance of lesions Annular and targetoid, erythematous and purpuric plaques Urticarial papules progressing to palpable purpura Nonspecific; morbilliform, urticarial, or scarlatiniform morphologies Tender, erythematous papules and plaques
Typical location Face, ears, distal extremities Lower extremities, buttocks Diffuse Limbs, face, neck
Duration of individual lesions 1‐3 wk 5 d Several days 3‐9 d (with treatment)
Duration of rash 1‐3 wk 4‐6 wk Days to weeks 3‐9 d (with treatment); recurrence common
Mucous membrane involvement No No Yes—lip and tongue erythema Rarely
Facial or acral edema Yes Yes Yes No
Fever Variable Variable Yes Variable
Associated signs/symptoms Malaise, irritability Malaise, arthralgias, abdominal pain Nonexudative conjunctivitis, cervical lymphadenopathy Malaise, myalgias, arthralgias
Inciting factors Infection, medications, immunizations Infection, medications, immunizations Infection Infection, immunodeficiency, medications, malignancy
Pathology Leukocytoclastic vasculitis; direct immunofluorescence typically negative Leukocytoclastic vasculitis; direct immunofluorescence may demonstrate IgA deposition Vasculitis with inflammatory infiltrate of neutrophils and macrophages Dermal edema, neutrophilic infiltrate, leukocytoclasis without vasculitis
Type of hypersensitivity reaction Type III Type III Unknown Type IV
Treatment Supportive care Organ‐directed support of renal, GI, joint manifestations Intravenous immunoglobulin and aspirin Systemic corticosteroids or potassium iodide
Risk for severe complications Low Moderate High High

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.